Luye Pharma Group Ltd.
Luye Pharma Group Ltd. (LYPHF) Revenue
Annual & quarterly revenue history · segment & region breakdown
LYPHF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsLuye Pharma Group Ltd. trailing twelve-month (TTM) revenue is $12.32B, an increase of 1.39% year-over-year from $6.15B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $6.15B | +$0.08B | +1.39% |
| 2024-12-31 | $6.06B | -$0.08B | -1.33% |
| 2023-12-31 | $6.14B | +$0.16B | +2.70% |
| 2022-12-31 | $5.98B | +$0.78B | +15.03% |
| 2021-12-31 | $5.20B | -$0.34B | -6.13% |
| 2020-12-31 | $5.54B | -$0.82B | -12.87% |
| 2019-12-31 | $6.36B | +$1.18B | +22.89% |
| 2018-12-31 | $5.17B | +$1.36B | +35.61% |
| 2017-12-31 | $3.81B | +$0.90B | +30.74% |
| 2016-12-31 | $2.92B | +$0.35B | +13.84% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare LYPHF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Luye Pharma Group Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Luye Pharma Group Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from Luye Pharma Group Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
LYPHF revenue · 4 questionsLYPHF's trailing twelve-month (TTM) revenue is $12.32B. That is an increase of 1.39% year-over-year from $6.15B in FY2025.
▸ Source: FMP · Luye Pharma Group Ltd. SEC filings · GAAP · Luye Pharma Group Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026